Fractyl Health, Inc. (GUTS): who owns it and who trades it
As of Nov 16, 2026, GUTS insiders reported 7 purchases worth $187K in the last 12 months. The largest buyer was William Bradley (Director), with $90K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Fractyl Health
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GUTS
75 funds and institutions reported GUTS shares worth $65.2M at the end of Q2 2026, about 52% of the company. The largest holder is Nantahala Capital Management, LLC with 14.2%.
Funds and institutions (13F) 52%Everyone else 48%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 22.58M | 14.23% | $17.9M | +69% |
| Catalio Capital Management, LP | 6.17M | 3.89% | $4.9M | +12% |
| Vanguard Capital Management LLC | 6.10M | 3.84% | $4.8M | +10% |
| Bank of America Corp | 6.03M | 3.80% | $4.8M | +4728% |
| Pale Fire Capital SE | 5.00M | 3.15% | $4M | -16% |
| General Catalyst Group Management, LLC | 4.88M | 3.08% | $3.9M | No change |
| Deer Management Co. LLC | 4.77M | 3.01% | $3.8M | No change |
| Maverick Capital Ltd | 3.97M | 2.51% | $3.2M | No change |
| M28 Capital Management LP | 1.86M | 1.17% | $1.5M | No change |
| BlackRock, Inc. | 1.80M | 1.14% | $1.4M | -16% |
| Woodline Partners LP | 1.78M | 1.12% | $1.4M | -20% |
| Jane Street Group, LLC | 1.73M | 1.09% | $1.4M | +4261% |
| Silverarc Capital Management, LLC | 1.64M | 1.03% | $1.3M | -4% |
| UBS Group AG | 1.58M | 1.00% | $1.3M | -3% |
| CM Management, LLC | 1.40M | 0.88% | $1.1M | No change |
| Geode Capital Management, LLC | 1.32M | 0.83% | $1M | -8% |
| Ikarian Capital, LLC | 1.10M | 0.69% | $874K | No change |
| Marshall Wace, LLP | 1.08M | 0.68% | $854K | +34% |
| Logos Global Management LP | 1.00M | 0.63% | $794K | No change |
| Brevan Howard Capital Management LP | 916,321 | 0.58% | $719K | +294% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GUTS insiders reported $187K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | William Bradley | Director | Purchase | 64,516 | $0.62 | $40K | Form 4 |
| Jun 12, 2026 | Ajay Royan | Director | Purchase | 23,000 | $0.85 | $19.6K | Form 4 |
| Jun 10, 2026 | William Bradley | Director | Purchase | 68,493 | $0.73 | $50K | Form 4 |
| Jun 10, 2026 | Ian Sheffield | Director | Purchase | 35,000 | $0.73 | $25.6K | Form 4 |
| Jun 10, 2026 | Harith Rajagopalan | CEO | Purchase | 25,000 | $0.73 | $18.2K | Form 4 |
| Jun 8, 2026 | Weber Lara Smith | CFO | Purchase | 20,000 | $0.69 | $13.8K | Form 4 |
| Dec 4, 2025 | Harith Rajagopalan | CEO | Purchase | 10,416 | $1.92 | $20K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| William Bradley | Director | $90K | – | Sep 14, 2026 |
| Harith Rajagopalan | Chief Executive Officer, Director | $38.2K | – | Jun 10, 2026 |
| Ian Sheffield | Director | $25.6K | – | Jun 10, 2026 |
| Ajay Royan | Director | $19.6K | – | Jun 12, 2026 |
| Weber Lara Smith | Chief Financial Officer | $13.8K | – | Jun 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GUTS short interest
Low short interest. 0.4% of GUTS shares are sold short: about 1 share in 272. Over the last 12 reports the number of shares short went down 81%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 585,071 GUTS shares were sold short, 0.4% of the shares outstanding, up 120.4% from the report before. At the average daily volume of 1.93M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 585,071 | 0.37% | +120% | 1.93M | 1.0 |
| Oct 15, 2026 | 265,311 | 0.17% | -88% | 218,634 | 1.2 |
| Sep 30, 2026 | 2.15M | 1.35% | -20% | 1.79M | 1.2 |
| Sep 15, 2026 | 2.70M | 1.69% | +22% | 1.78M | 1.5 |
| Aug 31, 2026 | 2.22M | 1.39% | -17% | 1.47M | 1.5 |
| Aug 14, 2026 | 2.66M | 1.67% | -15% | 977,477 | 2.7 |
| Jul 31, 2026 | 3.12M | 1.97% | +24% | 1.79M | 1.8 |
| Jul 15, 2026 | 2.52M | 1.59% | +9% | 1.95M | 1.3 |
| Jun 30, 2026 | 2.31M | 1.46% | -0% | 1.71M | 1.4 |
| Jun 15, 2026 | 2.32M | 1.47% | -4% | 1.62M | 1.4 |
| May 29, 2026 | 2.41M | 1.52% | -22% | 1.56M | 1.5 |
| May 15, 2026 | 3.10M | 1.95% | +3% | 2.98M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Fractyl Health company events
Fractyl Health filed 20 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Nov 6, 2026.
- Nov 6, 2026LeadershipThe Board of Directors of the Company increased the size of the Board from nine to ten and appointed Michael Wartell as a Class III director, with a term expiring at the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier… Filing
- Oct 22, 2026LeadershipRetirement of Executive Officer In connection with the workforce reduction, on October 21, 2026, Jay Caplan announced his retirement. effective October 30, 2026, from his executive roles as the Company’s President and Chief Product Officer. Filing
- Oct 16, 2026AnnouncementThe Company reported topline six-month results from its REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled pivotal study evaluating the safety and efficacy of Revita in maintaining weight loss after GLP-1 based therapy discontinuation. Filing
- Oct 1, 2026RulesChanged its bylaws or articles. Filing
- Sep 24, 2026VoteReported shareholder vote results. Filing
- Sep 11, 2026ListingAs previously disclosed, on March 13, 2026, Fractyl Health, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on… Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 15, 2026AnnouncementThe Company reported one-year data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita for weight maintenance following GLP-1 drug discontinuation. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- Jun 4, 2026AnnouncementThe Company announced positive one-year results from its open-label REVEAL-1 Cohort in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 11, 2026AnnouncementShared information with investors. Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Mar 17, 2026ListingFractyl Health, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid… Filing
- Feb 26, 2026AnnouncementShared information with investors. Filing
- Jan 29, 2026AnnouncementThe Company reported 6-month data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita ® for weight maintenance following GLP-1 drug discontinuation. Filing
- Jan 6, 2026LeadershipThe Board of Directors of Fractyl Health, Inc. appointed Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Filing
- Jan 5, 2026AnnouncementThe Company announced its strategic outlook for 2026, including anticipated clinical and regulatory milestones across its Revita and Rejuva programs and an update to its cash position and runway guidance. Filing
- Dec 16, 2025AnnouncementThe Company provided notice to the holders of its outstanding Tranche A Common Stock Purchase Warrants to purchase shares of the Company’s common stock, par value $0.00001 per share that it has achieved the performance targets to call such warrants for cancellation, and will cancel the Tranche A… Filing
- Dec 2, 2025AnnouncementThe Company issued a press release announcing positive 6-month data from the open-label REVEAL-1 Cohort. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Fractyl Health financials
Famous investors that hold GUTS
4 of the 50 well-known investors we track reported holding GUTS in their latest 13F filing. The largest position is Lee Ainslie's, worth $2.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | Q3 2026 | 3.97M | $2.2M | 0.0% | No change |
| Ken Griffin · Citadel Advisors | Q3 2026 | 342,814 | $187K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 242,275 | $132K | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 208,505 | $114K | 0.0% | +71% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named GUTS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 6.9% |
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 6.9% |
| Oct 13, 2026 | Catalio Capital Management, LP | 13G | 5.6% |
| Oct 13, 2026 | Catalio Capital Management, LP | 13G | 5.6% |
Questions about Fractyl Health, Inc. (GUTS) stock
Who owns the most GUTS stock?
The largest reported owner of Fractyl Health, Inc. (GUTS) is Nantahala Capital Management, LLC, with 14.2% of the company. In total, 75 funds and institutions reported holding GUTS at the end of Q2 2026, together about 52% of the shares. See the largest owners.
Are GUTS insiders buying or selling?
In the last 12 months, GUTS insiders reported 7 open-market purchases worth $187K and no sales. The latest trade was on Sep 14, 2026. See every trade.
What is the short interest in GUTS?
As of Oct 30, 2026, 585,071 GUTS shares were sold short, 0.4% of the shares outstanding, up 120.4% from the report before. At the average daily volume of 1.93M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold GUTS?
4 of the 50 well-known investors we track reported GUTS in their latest 13F filing, including Lee Ainslie, Ken Griffin, Israel Englander. The largest position is worth $2.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.